{"organizations": [], "uuid": "f9a4abc82b74ad1cfd3524f29e9ebcad34e4f8c3", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180416.html", "section_title": "Archive News &amp; Video for Monday, 16 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-biomup-fy-net-loss-of-consolidated/brief-biomup-fy-net-loss-of-consolidated-operations-widens-to-31-3-million-euros-idUSFWN1RT03J", "country": "US", "domain_rank": 408, "title": "BRIEF-Biom'up FY Net Loss Of Consolidated Operations Widens To 31.3 Million Euros", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.33, "site_type": "news", "published": "2018-04-16T14:26:00.000+03:00", "replies_count": 0, "uuid": "f9a4abc82b74ad1cfd3524f29e9ebcad34e4f8c3"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-biomup-fy-net-loss-of-consolidated/brief-biomup-fy-net-loss-of-consolidated-operations-widens-to-31-3-million-euros-idUSFWN1RT03J", "ord_in_thread": 0, "title": "BRIEF-Biom'up FY Net Loss Of Consolidated Operations Widens To 31.3 Million Euros", "locations": [], "entities": {"persons": [], "locations": [{"name": "europe", "sentiment": "none"}, {"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 16 (Reuters) - BIOM UP SA:\n* BIOMâ€™UP REPORTS 2017 FULL-YEAR RESULTS AND PROVIDES CORPORATE UPDATE\n* AS AT DECEMBER 31, 2017, CASH AND CASH EQUIVALENTS AMOUNTED TO EUR 32.9\n* 2018 FOCUS ON PRODUCT LAUNCHES, SCALE-UP OF MANUFACTURING AND HEMOSTATIC PRODUCT PORTFOLIO EXPANSION\n* FY NET LOSS OF CONS. OPERATIONS EUR 31.3 MILLION VERSUS EUR 14.0 MILLION YEAR AGO\n* FY REVENUES EUR 1.8 MILLION VERSUS EUR 3.1 MILLION YEAR AGO\n* FY OPERATING LOSS EUR 17.7 MILLION VERSUS EUR 13.9 MILLION YEAR AGO\n* RAISES C. EUR 100 MILLION THROUGH 2017 TO DATE THANKS TO IPO ON EURONEXT AND ADDITIONAL RAISES\n* SAYS COMMERCIAL ROLL-OUT OF HEMOBLAST BELLOWS IN EUROPE AND THE U.S. TO START IN MID-2018 Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-16T14:26:00.000+03:00", "crawled": "2018-04-17T12:24:16.000+03:00", "highlightTitle": ""}